# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

C. Measurand: Benzoylecgonine (cocaine metabolites)

E. Applicant: Ortho-Clinical Diagnostic

# F. Proprietary and Established Names:

VITROS Chemistry Products COCM Reagent   
VITROS Chemistry Products Calibrator Kit 26   
VITROS Chemistry Products FS Calibrator 1   
VITROS Chemistry Products DAT Performance Verifiers I. II, III, IV, and V

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 2 . 3 2 5 0$ , Cocaine and Cocaine Metabolite Test System 21 CFR $\ S 8 6 2 . 3 2 0 0$ , Clinical Toxicology Calibrator 21 CFR $\ S 8 6 2 . 3 2 8 0 $ , Clinical Toxicology Control Material   
2. Classification: Class II (Reagent, Calibrator) Class I, Reserved (Control)   
3. Product code: DIO; DKB; DIF   
4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use: VITROS Chemistry Products COCM Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi-quantitative or qualitative determination of benzoylecgonine (cocaine metabolites) in human urine using a cutoff of either $1 5 0 ~ \mathrm { { n g / m L } }$ or $3 0 0 ~ \mathrm { { n g / m L } }$ . Measurements obtained with the VITROS COCM method are used in the diagnosis and treatment of benzoylecgonine use or

overdose.

The VITROS Chemistry Products COCM assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result obtained with this assay. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.

VITROS Chemistry Products Calibrator Kit 26 is used to calibrate VITROS 5,1 FS Chemistry Systems for the qualitative or semi-quantative measurement of the drugs of abuse.

VITROS Chemistry Products FS Calibrator 1 is used in conjunction with VITROS Chemistry Products Calibrator Kits to calibrate VITROS 5,1 FS Chemistry Systems.

VITROS Chemistry Products DAT Performance Verifiers are assayed controls used to monitor performance of urine drugs of abuse screening assays on VITROS 5,1 FS Chemistry Systems.

3. Special conditions for use statement(s): This device is for prescription use by professional laboratory personnel. For in vitro diagnostic use only.

4. Special instrument requirements: Ortho-Clinical Diagnostics VITROS 5,1 FS Chemistry System

# I. Device Description:

The VITROS COCM Reagent is a dual-chambered package containing ready-to-use liquid reagents that are used to detect benzoylecgonine (cocaine metabolite) in urine. Sample, calibrators, and controls are automatically treated with surfactant (DAT Diluent 2) prior to addition of reagents. Treated sample is added to Reagent 1 containing antibody reactive to benzoylecgonine, glucose-6-phosphate and nicotinamide adenine dinucleotide $( \mathrm { N A D } ^ { + } )$ , followed by Reagent 2 containing benzoylecgonine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH).

VITROS Chemistry Products Calibrator Kit 26 is prepared from human urine to which drugs of abuse, metabolites of drugs of abuse, organic salts, surfactants and preservative have been added.

VITROS Chemistry Products FS Calibrator 1 is prepared from sodium chloride and processed water.

VITROS DAT Performance Verifiers I, II, III, IV & V are prepared from a human urine pool to which analytes, surfactant and preservative have been added.

The product labeling for the Calibrator Kit 26 and Performance Verifiers contain warnings regarding the presence of human sourced materials and recommend the use of Universal Precautions when handling these products.

# J. Substantial Equivalence Information:

1. Predicate device name(s): EMIT II Plus Cocaine Metabolite Assay Liquicheck Urine Toxicology Controls

2. Predicate 510(k) number(s): k031512; k022707

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the qualitativeand semi-quantitativeanalysis of methadone inhuman urine.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Liquid, ready to use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Homogeneous enzymeimmunoassay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antibody</td><td rowspan=1 colspan=1>Sheep polyclonal</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrumentation</td><td rowspan=1 colspan=1>VITROS 5,1 FSChemistry Systems</td><td rowspan=1 colspan=1>Multiple automatedclinical chemistryanalyzers</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Six levels</td><td rowspan=1 colspan=1>Five levels</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Five levels</td><td rowspan=1 colspan=1>Two levels</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CSLI EP9-A2: Method Comparison and Bias Estimation Using Patient Samples   
CLSI EP5-A: Evaluation of Precision Performance of Clinical Chemistry Devices   
CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures, A Statistical Approach   
CLSI EP7-P: Interference Testing in Clinical Chemistry   
CLSI EP17-A: Protocols for Demonstration, Verification and Evaluation of Limits of Detection and Quantitation   
CLSI EP12-A: User Protocols for Evaluation of Qualitative Test Performance

# L. Test Principle:

The VITROS COCM assay is a homogeneous enzyme immunoassay that is performed using the VITROS Chemistry Products COCM Reagent in conjunction with the VITROS Chemistry Products Calibrator Kit 26 and VITROS Chemistry Products FS Diluent Pack 4 (DAT Diluent/DAT Diluent 2) on VITROS 5,1 FS Chemistry Systems.

The assay is based on competition between benzoylecgonine in the treated urine sample and the benzoylecgonine labeled with the enzyme glucose-6-phosphate dehydrogenase (G6P-DH) for antibody binding sites. Enzyme activity decreases upon binding to the antibody, therefore the concentration of benzoylecgonine in the urine sample is directly proportional to measured enzyme activity. Active enzyme converts oxidized nicotinamide adenine dinucleotide $( \mathrm { N A D } ^ { + } )$ ) to NADH, resulting in an absorbance change that is measured spectrophotometrically at $3 4 0 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Imprecision was evaluated with human urine-based quality control materials on the VITROS 5,1 FS Chemistry System following CLSI Protocol EP5 and CLSI protocol EP12. The sponsor cautions that variables such as instrument maintenance, environment, reagent storage/handling, control material reconstitution, and sample handling can affect the reproducibility of test results.

Imprecision for COCM: Semi-Quantitative   

<table><tr><td rowspan="2">System</td><td colspan="3">Conventional Units (ng/mL) and SI Units (μg/L)</td><td rowspan="2">Within Lab CV%**</td><td rowspan="2">No. Observ.</td><td rowspan="2">No. Days</td></tr><tr><td>Mean Conc.</td><td>Within Day SD*</td><td>Within Lab SD**</td></tr><tr><td rowspan="5">VITROS 5,1 FS</td><td>98</td><td>4.8</td><td>9.4</td><td>9.6</td><td>86</td><td>22</td></tr><tr><td>181</td><td>5.6</td><td>11.5</td><td>6.4</td><td>86</td><td>22</td></tr><tr><td>227</td><td>7.1</td><td>13.5</td><td>5.9</td><td>86</td><td>22</td></tr><tr><td>369</td><td>10.3</td><td>19.2</td><td>5.2</td><td>84</td><td>22</td></tr><tr><td>567</td><td>21.0</td><td>46.7</td><td>8.2</td><td>86</td><td>22</td></tr></table>

\* Within Day imprecision was determined using one to two runs per day with two replications per run. \*\* Within Lab imprecision was determined using a single lot of reagents with one analyzer and four calibrations.

Qualitative imprecision was assessed using test fluids targeted $1 1 \pm 2 5 \%$ of each cutoff. The imprecision was determined as the confidence level of obtaining a correct result with known positive or negative fluids.

Imprecision for COCM: Qualitative\*   

<table><tr><td rowspan=1 colspan=1>System</td><td rowspan=1 colspan=1>Cutoff Level(ng/mL &amp;g/L)</td><td rowspan=1 colspan=1>Test Fluidat± 25%Cutoff</td><td rowspan=1 colspan=1>Number ofObservations</td><td rowspan=1 colspan=1>Number ofCorrectInterpretations</td><td rowspan=1 colspan=1>Confidence Level</td></tr><tr><td rowspan=4 colspan=1>VITROS 5,1FS</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>&gt;95% negative reading</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>&gt;95% positive reading</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>&gt;95% negative reading</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>&gt;95% positive reading</td></tr></table>

\* Determined using one to two runs per day with two replicates per run for 22 days, using a single lot of reagents with one analyzer and four calibrations

$b$ . Linearity/assay reportable range:

The sponsor followed CLSI EP6-A in determining the linear range of their device. Two urine pools were prepared with benzoylecgonine concentrations at the low $( 0 \mathrm { n g / m L } )$ and high ( $1 2 0 0 ~ \mathrm { n g / m L ) }$ end of the calibration range. The two pools were mixed to give 18 admixtures of intermediate concentrations. Linearity was evaluated using three assay reagent lots and comparing the measured results against the expected results from 18 pooled samples. A linear regression was performed and the results indicated acceptable linearity across the benzoylecgonine concentration range tested 47 to $1 0 0 7 ~ \mathrm { { n g / m L } }$ . This linearity determination in conjunction with determination of the limit of quantation was used to establish the semi-quantitative range of the VITROS COCM assay $( 5 0 { \cdot } 1 0 0 0 ~ \mathrm { n g / m L } )$ ).

# Recovery study

Eleven admixtures were prepared from two human urine pools. Benzoylecgonine values for the admixtures were calculated based on the gravimetric addition with GC/MS verification of the high pool and the percentage of high pool to the low pool (a drug-free urine based matrix). Percent recovery was calculated using the concentration obtained by the VITROS Chemistry Products COCM Assay versus the calculated benzoylecgonine value.

Recovery of Benzoylecgonine   

<table><tr><td rowspan=1 colspan=1>Benzoylecgonine(ng/mL)</td><td rowspan=1 colspan=1>VITROS COCM Assay(ng/mL)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>113.3</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>105.1</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>219</td><td rowspan=1 colspan=1>109.4</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>316</td><td rowspan=1 colspan=1>105.3</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>403</td><td rowspan=1 colspan=1>100.6</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>484</td><td rowspan=1 colspan=1>96.9</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>593</td><td rowspan=1 colspan=1>98.8</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>103.0</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>96.8</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>880</td><td rowspan=1 colspan=1>97.8</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>998</td><td rowspan=1 colspan=1>99.8</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The assigned values for the calibrators and controls are traceable to the Cerilliant benzoylecgonine standard catalogue B-028 and are verified by GC/MS.

Real time and accelerated stability studies were conducted; protocols and acceptance criteria were described and found to be acceptable. These studies support the manufacturer’s stability claims. Real time studies are ongoing.

# d. Detection limit:

The limit of quantitation (LOQ) is defined as the minimum amount of analyte whose presence can be quantitatively determined with stated acceptable precision and trueness under defined experimental conditions.

The limit of detection (LOD) is the minimum amount of analyte whose presence can be quantitatively detected under defined conditions. For the VITROS COCM assay, the LOD was determined to be $3 1 ~ \mathrm { n g / m L }$ . The limit of quantitation (LOQ) was determined to be $5 0 ~ \mathrm { n g / m L }$ .

# e. Analytical specificity:

The specificity of the VITROS COCM assay for various cocaine metabolites and structurally similar compounds was estimated by generating a dose response curve for each of the compounds listed below. The quantity $( \mathrm { n g / m L } )$ of compound that produces a value equivalent to the benzoylecgonine quantity $( \mathrm { n g / m L } )$ at each cutoff value is listed below. The combined effects of more than one compound detected in a sample may cause levels lower than those listed below to produce a value approximately equivalent to or greater than the cutoff value.

Substances that Cross-react with COCM   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Quantity(ng/mL)equivalent to150 ng/mL ofBE</td><td rowspan=1 colspan=1>% cross-reactivity*</td><td rowspan=1 colspan=1>Quantity(ng/mL)equivalent to300 ng/mL ofBE</td><td rowspan=1 colspan=1>% cross-reactivity*</td></tr><tr><td rowspan=1 colspan=1>Benzoylecgonine (BE)</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>m-hydroxybenzoylecgonine</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>ecognine</td><td rowspan=1 colspan=1>4450</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>15,325</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>cocaine</td><td rowspan=1 colspan=1>39,500</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>81,300</td><td rowspan=1 colspan=1>0.4</td></tr><tr><td rowspan=1 colspan=1>ecognine methyl ester</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.2%</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.3%</td></tr><tr><td rowspan=1 colspan=1>cocaethylene</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.2%</td><td rowspan=1 colspan=1>&gt;100,000</td><td rowspan=1 colspan=1>&lt;0.3%</td></tr></table>

\* The VITROS COCM Assay cutoff value $\mathrm { ( n g / m L ) }$ ) divided by the amount of cross-reactant $\scriptstyle ( \mathrm { n g / m L } )$ that produces a value equivalent to the cutoff value, multiplied by 100.

The substances listed in the table, at the concentrations shown, were tested according to CLSI Protocol EP7 and found not to interfere (defined by the sponsor as bias $< 2 8 . 7 \ \mathrm { n g / m L }$ at $1 5 0 ~ \mathrm { { n g / m L } }$ COCM and bias $< 5 7 . 4 ~ \mathrm { n g / m L }$ at $3 0 0 ~ \mathrm { { n g / m L } }$ COCM).

Substances that Do Not Interfere with COCM   

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=3>Concentration</td><td rowspan=2 colspan=2>′</td><td rowspan=2 colspan=1>′</td><td></td><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=2>Concentration</td></tr><tr><td></td></tr><tr><td rowspan=3 colspan=1>ammonia</td><td rowspan=3 colspan=1>570 mg/dL</td><td rowspan=3 colspan=2>335 μmol/L</td><td rowspan=3 colspan=2>b</td><td rowspan=3 colspan=1>b</td><td></td><td rowspan=3 colspan=1>lidocaine</td><td></td><td></td></tr><tr><td rowspan=2 colspan=2></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>427μmol/L</td></tr><tr><td rowspan=2 colspan=1>amobarbitol</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>442 mol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td><td rowspan=2 colspan=2>magnesium</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>ascorbic acid</td><td rowspan=2 colspan=1>500 mg/dL</td><td rowspan=2 colspan=2>28 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=1>b</td><td rowspan=2 colspan=2>meperidine</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=1 colspan=1>benzocaine</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=2>605μmol/L</td><td rowspan=1 colspan=3>b</td><td></td><td rowspan=1 colspan=1>methoxyphenamine HCl</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>371mol/L</td></tr><tr><td rowspan=2 colspan=1>bilirubin</td><td rowspan=2 colspan=1>26 mg/dL</td><td rowspan=2 colspan=2>445 μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=1>b</td><td rowspan=2 colspan=2>metronidazole</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=1 colspan=1>brompheniramine</td><td rowspan=1 colspan=1>0.01 mg/dL</td><td rowspan=1 colspan=2>313μmol/L</td><td rowspan=1 colspan=3>b</td><td></td><td rowspan=1 colspan=1>NaCl</td><td rowspan=1 colspan=1>6000 mg/dL</td><td rowspan=1 colspan=1>1027mmol/L</td></tr><tr><td rowspan=2 colspan=1>calcium</td><td rowspan=2 colspan=1>30 mg/dL</td><td rowspan=2 colspan=2>8 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>nylidrine HCl</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>ciprofloxacin</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>300μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>ofloxacin</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>citric Acid</td><td rowspan=2 colspan=1>100 mg/dL</td><td rowspan=2 colspan=2>5 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>oxalic Acid</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>cloxacillin</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>229μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>pH = 4</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>creatinine</td><td rowspan=2 colspan=1>300 mg/dL</td><td rowspan=2 colspan=2>27 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>pH = 9</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>desipramine HCI</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>330μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=1>b</td><td rowspan=2 colspan=2>phenylbutazone</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=2 colspan=1>dextromethorphan</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>369μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>phenyltoloxamine</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>dicyclomine</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>289μmol/L</td><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>phosphate</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>diethylproprione</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>487μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>promethazine</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>doxylamine</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>370μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>propranolol HCl</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>ethacrynic acid</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>330μmol/L</td><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>pyruvate</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>ethanol</td><td rowspan=2 colspan=1>780 mg/dL</td><td rowspan=2 colspan=2>169 mmol/L</td><td rowspan=2 colspan=2></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>ranitidine HCl</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>glucose</td><td rowspan=2 colspan=1>4000 mg/dL</td><td rowspan=2 colspan=2>222 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=1>b</td><td rowspan=2 colspan=2>riboflavin</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=2 colspan=1>hemoglobin</td><td rowspan=2 colspan=1>500 mg/dL</td><td rowspan=2 colspan=2>5 g/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>tolmetin/tolectin</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>human IgG</td><td rowspan=2 colspan=1>200 mg/dL</td><td rowspan=2 colspan=2>2 g/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>trihexylphenidyl</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>human serumalbumin</td><td rowspan=1 colspan=1>200 mg/dL</td><td rowspan=1 colspan=2>2 g/L</td><td rowspan=1 colspan=3></td><td></td><td rowspan=1 colspan=1>trimethobenzamide HCl</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>257μmol/L</td></tr><tr><td rowspan=2 colspan=1>imipramine HCl</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>357μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>tripelannamine</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>indomethacin</td><td rowspan=2 colspan=1>10 mg/dL</td><td rowspan=2 colspan=2>280μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>triprolidine</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>iron</td><td rowspan=2 colspan=1>100 μg/dL</td><td rowspan=2 colspan=2>18 μmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>b</td><td rowspan=2 colspan=2>tyramine</td></tr><tr><td rowspan=1 colspan=2></td><td></td><td></td></tr><tr><td rowspan=2 colspan=1>KCI</td><td rowspan=2 colspan=1>1118 mg/dL</td><td rowspan=2 colspan=2>150 mmol/L</td><td rowspan=2 colspan=2>b</td><td rowspan=1 colspan=2></td><td rowspan=2 colspan=1>b</td><td rowspan=2 colspan=2>urea</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr><tr><td rowspan=4 colspan=1>L-hyoscyamine</td><td rowspan=4 colspan=1>10 mg/dL</td><td rowspan=4 colspan=2>346μmol/L</td><td></td><td rowspan=1 colspan=2></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=3 colspan=2>cYanmalowb</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td rowspan=2 colspan=1>b</td><td></td><td rowspan=2 colspan=1>uric acid</td><td rowspan=2 colspan=1>120 mg/dL</td><td rowspan=2 colspan=1>7 mmol/L</td></tr><tr><td rowspan=1 colspan=2></td><td></td></tr></table>

f. Assay cut-off: The stated cutoff of this assay is either $1 5 0 \mathrm { n g / m L }$ or $3 0 0 ~ \mathrm { { n g / m L } }$ .

2. Comparison studies:

a. Method comparison with predicate device:

A total of 108 human urine samples were assayed using the VITROS Chemistry Products COCM Reagent and a commercially available immunoassay method. Percent agreement was evaluated at assay cutoff values of 150 and $3 0 0 ~ \mathrm { { n g / m L } }$ .

Commercial Method Comparison for COCM   

<table><tr><td rowspan=2 colspan=2>CutoffValue(ng/mL)</td><td rowspan=1 colspan=4>Commercial Method**</td><td rowspan=1 colspan=3>%Agreement</td></tr><tr><td rowspan=1 colspan=1>LowNegative</td><td rowspan=1 colspan=1>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>%AgreementNegative</td><td rowspan=1 colspan=1>%AgreementPositive</td><td rowspan=1 colspan=1>%Agreementverall</td></tr><tr><td rowspan=3 colspan=1>150</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;75 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)75-150 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)150-225 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;225 ng/mL</td><td rowspan=3 colspan=1>97.6%</td><td rowspan=3 colspan=1>100.0%</td><td rowspan=3 colspan=1>99.1%</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>56</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>300</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;500 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)150-300 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)300-450 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;450 ng/mL</td><td rowspan=3 colspan=1>100.0%</td><td rowspan=3 colspan=1>100.0%</td><td rowspan=3 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

\* See Summary of Discordant Results below \*\* Syva® Emit® II Plus Cocaine Metabolite Assay

Summary of Discordant Results: Commercial Method   

<table><tr><td>Cutoff Value (ng/mL)</td><td>VITROS COCM Assay (ng/mL)</td><td>Commercial Method (ng/mL)</td></tr><tr><td>150</td><td>154</td><td>141</td></tr></table>

A total of 116 human urine samples were assayed using the VITROS Chemistry Products COCM Reagent and a GC/MS reference method for benzoylecgonine (a cocaine metabolite). Percent agreement was evaluated at assay cutoff values of 150 and $3 0 0 ~ \mathrm { { n g / m L } }$ .

To challenge performance at the $1 5 0 ~ \mathrm { { n g / m L } }$ cutoff value, 34 of the 116 samples tested had concentrations within $+ / - 5 0 \%$ of the cutoff value, 21 samples below the cutoff value and 13 samples above the cutoff value.

To challenge performance at the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff value, 34 of the 116 samples tested had concentrations within $+ / - 5 0 \%$ of the cutoff value, 25 samples below the cutoff value and 9 samples above the cutoff value

GC/MS Reference Method Comparison for COCM   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=4>GC/MS Reference Method</td><td rowspan=1 colspan=3>% Agreement</td></tr><tr><td rowspan=1 colspan=2>CutoffValue(ng/mL)</td><td rowspan=1 colspan=1>LowNegative</td><td rowspan=1 colspan=1>Near CutoffNegative</td><td rowspan=1 colspan=1>Near CutoffPositive</td><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>% AgreementNegative</td><td rowspan=1 colspan=1>% AgreementPositive</td><td rowspan=1 colspan=1>% AgreementOverall</td></tr><tr><td rowspan=3 colspan=1>150</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;-50%)&lt;75 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)75-150 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)150-225 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;225 ng/mL</td><td rowspan=3 colspan=1>69.1%</td><td rowspan=3 colspan=1>96.7%</td><td rowspan=3 colspan=1>83.6%</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>14*</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>48</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>300</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(&lt;50%)&lt;150 ng/mL</td><td rowspan=1 colspan=1>(-50% to cutoff)150-300 ng/mL</td><td rowspan=1 colspan=1>(cutoff to +50%)300-450 ng/mL</td><td rowspan=1 colspan=1>(&gt;+50%)&gt;450 ng/mL</td><td rowspan=3 colspan=1>76.3%</td><td rowspan=3 colspan=1>100.0%</td><td rowspan=3 colspan=1>83.6%</td></tr><tr><td rowspan=1 colspan=1>VITROSPositive</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>17*</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>VITROSNegative</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

\*See GC/MS Summary of Discordant Results below

<table><tr><td colspan="4" rowspan="1">Summary of Discordant Results: GC/MS</td></tr><tr><td colspan="1" rowspan="1">CutoffValue(ng/mL)</td><td colspan="1" rowspan="1">VITROSCOCM(ng/mL)</td><td colspan="1" rowspan="1">GC/MS(ng/mL)</td><td colspan="1" rowspan="1">Major DrugPresent byGC/MS</td></tr><tr><td colspan="1" rowspan="19">150</td><td colspan="1" rowspan="1">104</td><td colspan="1" rowspan="1">170</td><td colspan="1" rowspan="19">benzoylecgonine</td></tr><tr><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">187</td></tr><tr><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">142</td></tr><tr><td colspan="1" rowspan="1">172</td><td colspan="1" rowspan="1">131</td></tr><tr><td colspan="1" rowspan="1">178</td><td colspan="1" rowspan="1">90</td></tr><tr><td colspan="1" rowspan="1">184</td><td colspan="1" rowspan="1">81</td></tr><tr><td colspan="1" rowspan="1">184</td><td colspan="1" rowspan="1">61</td></tr><tr><td colspan="1" rowspan="1">184</td><td colspan="1" rowspan="1">134</td></tr><tr><td colspan="1" rowspan="1">185</td><td colspan="1" rowspan="1">61</td></tr><tr><td colspan="1" rowspan="1">191</td><td colspan="1" rowspan="1">119</td></tr><tr><td colspan="1" rowspan="1">199</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="1" rowspan="1">204</td><td colspan="1" rowspan="1">97</td></tr><tr><td colspan="1" rowspan="1">217</td><td colspan="1" rowspan="1">126</td></tr><tr><td colspan="1" rowspan="1">234</td><td colspan="1" rowspan="1">146</td></tr><tr><td colspan="1" rowspan="1">250</td><td colspan="1" rowspan="1">117</td></tr><tr><td colspan="1" rowspan="1">267</td><td colspan="1" rowspan="1">92</td></tr><tr><td colspan="1" rowspan="1">276</td><td colspan="1" rowspan="1">134</td></tr><tr><td colspan="1" rowspan="1">314</td><td colspan="1" rowspan="1">76</td></tr><tr><td colspan="1" rowspan="1">442</td><td colspan="1" rowspan="1">62</td></tr><tr><td colspan="1" rowspan="5">300</td><td colspan="1" rowspan="1">314</td><td colspan="1" rowspan="1">76</td><td colspan="1" rowspan="5">benzoylecgonine</td></tr><tr><td colspan="1" rowspan="1">323</td><td colspan="1" rowspan="1">184</td></tr><tr><td colspan="1" rowspan="1">350</td><td colspan="1" rowspan="1">299</td></tr><tr><td colspan="1" rowspan="1">368</td><td colspan="1" rowspan="1">277</td></tr><tr><td colspan="1" rowspan="1">373</td><td colspan="1" rowspan="1">290</td></tr><tr><td colspan="1" rowspan="14"></td><td colspan="1" rowspan="1">377</td><td colspan="1" rowspan="1">169</td><td colspan="1" rowspan="14"></td></tr><tr><td colspan="1" rowspan="1">393</td><td colspan="1" rowspan="1">253</td></tr><tr><td colspan="1" rowspan="1">423</td><td colspan="1" rowspan="1">232</td></tr><tr><td colspan="1" rowspan="1">434</td><td colspan="1" rowspan="1">299</td></tr><tr><td colspan="1" rowspan="1">441</td><td colspan="1" rowspan="1">235</td></tr><tr><td colspan="1" rowspan="1">442</td><td colspan="1" rowspan="1">62</td></tr><tr><td colspan="1" rowspan="1">445</td><td colspan="1" rowspan="1">181</td></tr><tr><td colspan="1" rowspan="1">452</td><td colspan="1" rowspan="1">259</td></tr><tr><td colspan="1" rowspan="1">479</td><td colspan="1" rowspan="1">221</td></tr><tr><td colspan="1" rowspan="1">531</td><td colspan="1" rowspan="1">224</td></tr><tr><td colspan="1" rowspan="1">555</td><td colspan="1" rowspan="1">186</td></tr><tr><td colspan="1" rowspan="1">575</td><td colspan="1" rowspan="1">214</td></tr><tr><td colspan="1" rowspan="1">788</td><td colspan="1" rowspan="1">243</td></tr><tr><td colspan="1" rowspan="1">&gt;1000</td><td colspan="1" rowspan="1">296</td></tr></table>

$b$ . Matrix comparison: Not applicable; this device is for use with urine only.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.